Tyrosine kinase inhibitor (TKI) monotherapy still has a place in front-line therapy in patients with metastatic renal cell carcinoma (mRCC), according to a presentation at the 2017 International Kidney Cancer Symposium.
Bradley A. McGregor, MD, the clinical director of Dana-Farber Cancer Institute’s Lank Center for Genitourinary Oncology, in Boston, presented data underscoring the continued value of TKI monotherapy for mRCC in the era of immunotherapy.
In the CheckMate 214 trial of